Linux Image Engineer

We are seeking a Linux Image Engineer to design, build, and maintain secure, minimal Linux environments that power the connectivity subsystem for our medical devices. This subsystem acts as a secure gateway between on-premise equipment and cloud services, ensuring reliable and compliant data exchange within hospital networks. This role owns the full lifecycle of embedded Linux images, including development, hardening, validation, compliance documentation, and deployment in regulated environments., * Design and maintain minimal, hardened Linux images for embedded systems (ARM64, NVIDIA Jetson).

• Build images using Yocto, Ubuntu, or similar frameworks.
• Configure kernel, drivers, and system services.
• Optimize system performance and reduce attack surface.
• Implement security controls (secure boot, TPM, encryption, access controls)
• Develop CI/CD pipelines and automated validation testing.
• Generate SBOMs, track and manage vulnerabilities (CVE remediation).
• Author, own and support regulatory compliance (FDA, IEC standards) and build process documentation.
• Enable secure OTA updates and field deployments.
• Collaborate with cross-functional engineering and regulatory teams.

Do you have experience in System hardening?, Do you have a Bachelor's degree?, Required:

• Bachelors degree, preferably in a related field
• 3 years of directly related experience
• Strong Linux internals (kernel, boot, networking).
• Experience with embedded Linux (Yocto, Buildroot).
• System hardening and cybersecurity expertise.
• CI/CD and automated testing experience.
• Experience in regulated environments or willingness to learn.
• Strong documentation and traceability skills.

Preferred:

• NVIDIA Jetson experience.
• HL7, FHIR, or DICOM knowledge.
• Cloud IoT experience (Azure, AWS).

Pulled from the full job description

• 401(k)
• Paid time off
• Vision insurance
• Dental insurance
• Disability insurance

HistoSonics is a commercial-stage medtech company advancing the Edison® System, a novel non-invasive sonic beam therapy based on histotripsy. Since receiving FDA De Novo grant for the non-invasive destruction of liver tumors in 2023, the company has progressed beyond initial market entry into commercial expansion, reimbursement momentum, and ongoing clinical and pipeline development. In addition to its current liver tumor indication, HistoSonics is pursuing future indications across multiple applications including kidney, pancreas, prostate, neuro, women's health, and other significant underserved human health areas, to realize the broader potential histotripsy across multiple disease states and medical specialties. We offer an exciting work culture where cutting-edge science meets real-world application, and each team member's contribution is important to our success in ensuring our physicians and their patients get what they need most.